RCLS on National Heart Month
Randox Clinical Laboratories Service (RCLS) has been built on 35 years of Randox Laboratories experience. The aim of our RCLS team is to meet the time sensitive, custom-made requirements of research and clinical projects. They specialize in biomarker and multiplex testing to provide full laboratory services to aid the project aims and timelines whilst saving time and money. Currently, there are four laboratories across the UK located in Liverpool, London, Holywood and the Randox Science Park in Antrim where knowledgeable and proficient teams are situated and are available accordingly to provide support and guidance.
Continuing with National Heart Month, RCLS would like to take the opportunity to reinforce the importance of taking care of your hearts health. (WHO) highlighted Ischemic heart disease and stroke are the world’s biggest killers. An estimated 17 million people die of cardiovascular disease particularly heart attacks and strokes every year.1
Lipoprotein (a) which is also known as Lp(a) consists of two protein molecules, apolipoprotein (a) or apo(a). It is a large lipoprotein particle made by the liver. The Apo(a) particle is a very sticky protein particle, thought to be involved in the clotting system and its addition can be likened to adding a patch of Velcro on to a normal LDL particle. 2 Having some cholesterol and Lp(a) in your blood is normal however, high levels of LDL cholesterol would increase your risk of having some serious heart implications.
It has been highlighted in recent research that blood levels of Lp(a) could be an important indication as it is currently the strongest inherited risk factor for developing cardiovascular disease and stroke. Globally, one in five people have high levels of Lp(a) greater than 50mg 3. As a result, gradually narrow the arteries, limiting blood supply to the brain, heart kidney, legs and can also increase the risk of blood clots, heart attack and stroke.
High Lp(a) can also be related to other common risks factors of cardiovascular diseases for example, smoking, diet, diabetes, high blood pressure and lack of exercise. Therefore, it is possible that those who appear “healthy” can have high Lp(a) in their genes and still be at high risk of cardiovascular diseases.
The Lipoprotein(a) Foundation strongly emphasized that the Lp(a) test would be advised if you have the following:
- If there is a family who has history with cardiovascular disease including stroke, heart attack, circulation problems in the legs and/or narrowing of the aorta, at a young age. If someone in your family has high Lp(a), their children have a 50/50 chance inheriting it.
- Stroke or heart attack are classical risk factors including high LDL-cholesterol, obesity, diabetes and smoking have been eliminated
- High levels of LDL-cholesterol following treatment with statins or other LDL lowering medications
Randox Clinical Laboratory Services offer you our Lipoprotein (a) assay as well as our variety of analysers across all RCLS laboratories including our RX Series and Evidence Series as well as third party analysers ensuring the testing abilities are diverse. The Randox Lp(a) assay is one of the only methodologies on the market that detects the non-variable part of the Lp(a) molecule providing accurate and consistent results.
If you would like more information on RCLS please contact email@example.com
This February, Randox Health are focusing on Heart Health. Heart health is becoming a much greater talked about subject because of health trends and figures. There are around 7 million people living with heart and circulatory disease in the UK. Heart and circulatory disease causes more than a quarter (26%) of all deaths in the UK; that’s nearly 160,000 deaths each year – an average of 435 people each day or one death every three minutes. Facts like these from BHF show us how how important our hearts are! Maintaining and having a healthy heart is essential to cut down your risk of heart disease.
Ways to Improve your Health
There are a number of things you can do to lower your risk of getting heart disease, and at the same time improve overall health. Lets look at three ways to lower your risk and help you become healthier:
- Managing a healthy weight
- Eating healthier
- Getting active
What You Can Do
All three of the above will lower your risk of heart disease and all are linked so by improving one it will help the others. To manage a healthy weight, first you need to work out what a healthy weight is for you. There are two main ways to tell whether you need to lose weight: your Body Mass Index (BMI), and your waist measurement. the risk of heart disease begins to increase at a BMI of 23, and people with a BMI of 27.5 will be at high risk.
Men with a waist of over 94 cm are at an increased risk of heart diseases and over 102 cm are at a severe risk. Women with a waist over 80 cm are at an increased risk and at 88 cm are at a severe risk. If you fall in these risk areas, eating well and being more physically active can help you reduce your weight.
A healthy diet can help reduce your risk of developing coronary heart disease and stop you gaining weight. This also reduces your risk of diabetes and high blood pressure. A well-balanced diet should include at least 5 portions of fruit and veg a day. Try to vary the types of fruit and veg you eat.
You should try to replace saturated fats with small amounts of mono and polyunsaturated fats. Try and cut down on foods that contain trans fats as it can raise your cholesterol levels. Lowering your salt intake can improve your blood pressure and lower your chance of coronary heart disease. Eating a healthy well-balanced diet can make it a lot easier to control and maintain your weight.
Get Active! The BHF say that physical activity can help reduce your risk of heart and circulatory disease. It also links in and helps you control your weight! Being active reduces blood pressure and cholesterol and can even improve your mental health. If you do all three of these points not only will it lower your risks of heart disease but will improve your overall health!
Randox Health: What We Do and How We Can Help
This month we are focusing on heart heart, so make sure to check out our blogs with information about how to keep a healthy heart. If you’re worried about your heart health or have a family history of heart disease, contact a member of our team today for more information on how we could help you! We are determined to help you get to the heart of the matter and see what’s really going on with your heart. This Valentines day give a gift to the one you love that really matters, the gift of health.
Find out more here: https://www.randoxhealth.com/our-packages/
“CVDs are the number 1 cause of death globally: more people die annually from CVDs than from any other cause”. In 2015, roughly 17.7 million people died from CVD, representing 31% of all global deaths: 7.4 million were due to coronary heart disease and 6.7 million were due to stroke. (WHO, 2017)
Cardiac health and regular cardiovascular screening is important to enable risk factors to be detected in their earliest stages. There are a few factors which contribute to CVD. These include: smoking, unhealthy diet, excessive alcohol consumption, low physical activity levels. Whilst there are only a few factors contributing to CVD, these can be maintained by the patient through living a healthy lifestyle including: quitting smoking, consuming no more than the recommended allowance of alcohol, cutting out junk food, and exercising for 30 minutes a day, 3 – 5 days a week. In a perfect world, this would be easy and CVD would not be a global problem. However, due to busy lifestyles, cravings, reduced willpower, and convenience, not all individuals in today’s world will be able to avoid CVDs. Therefore, it is vitally important that individuals are tested for CVDs to detect them in the earliest stages to reduce damage, prevent further damage, or even death. Furthermore, many individuals suffer from inherited cardiac risk factors, which stresses the need for accurate testing of both traditional and novel cardiac risk biomarkers.
Randox offer the complete solution to cardiac risk assessment including: RX analysers, traditional and novel reagents, internal quality control (Acusera), and external quality control (RIQAS).
Randox has developed the RX series range of clinical chemistry analysers for high-quality semi-automated and fully automated testing. Choose between the RX misano, RX monaco, RX daytona+, RX imola, and the RX modena depending on the throughput of your laboratory. The RX series offers a suitable analyser for your laboratory’s needs. For more information on the Randox RX series, please click here or email firstname.lastname@example.org
As previously mentioned, early assessment of cardiac risk is vital. Randox offer a range of novel risk biomarkers for both very early and the genetic assessment of cardiac risk.
The niche Adiponectin assay allows for the early assessment of CVD. Adiponectin levels are inversely correlated with abdominal visceral fat which has proven to be a strong predictor of T2DM. Body-Mass Index (BMI) is a common method for determining which patients are classified as underweight, healthy, overweight or obese, however, BMI does not take into account gender, ethnicity or activity levels. For example, measuring the BMI of athletes who have a high BMI due to muscle weighing heavier than fat would classify them as obese which is inaccurate. Measuring adiponectin levels is therefore a much more reliable indicator of at-risk patients compared to BMI.
LDL cholesterol is often referred to as the ‘bad cholesterol’. High concentrations of LDL-cholesterol is considered to be the most important clinical predictor, of all single parameters, with respect to coronary atherosclerosis. However, sLDL is a smaller, more dense subfraction of LDL-cholesterol. sLDL particles more readily permeate the inner arterial wall and are more susceptible to oxidation. Individuals with a predominance of sLDL have a 3-fold increased risk of myocardial infarction. Measurement of sLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly.
Elevated levels of Lp(a) are considered to be both a casual risk factor and independent genetic marker of atherosclerotic disorders. The major challenge associated with Lp(a) measurement is the size variation of apo(a) within Lp(a). Dependent upon the size of apo(a) in the assay calibrator, many assays under or overestimate apo(a) size in the patient sample. Numerous commercially available products suffer apo(a) size related bias, resulting in an over estimation of Lp(a) in samples with large apo(a)molecules and an under estimation in samples with small apo(a) molecules. The antibody used in the Randox method detects the complete Lp(a) molecule providing accurate and consistent results. This was proven by the IFCC who developed a gold standard ELISA reference assay and compared 22 commercially available tests. The Randox Lp(a) method displayed the least (minimal) amount of apo(a) size related bias, proving it be a superior offering.
HDL3 Cholesterol is a smaller and more dense subfraction of the HDL particle. HDL is the scavenger of cholesterol within arterial walls and the levels of HDL3 is too low, the ability to remove this cholesterol is reduced. Therefore, it is widely accepted that there is an inverse correlation between HDL3 and CVD risk.
Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.
Acusera – Internal Quality Control
The Acusera cardiac controls have been designed to cover a wide range of cardiac markers at clinical decision levels, eliminating the extra expense of an additional low level control. The controls are available in a both liquid ready-to-use and lyophilized formats making them ideal for all situations and manufactured from 100% human serum a matrix similar to that of the patient is guaranteed. For more information on the Randox Acusera internal quality control, please click here or email email@example.com
RIQAS – External Quality Control
The RIQAS Liquid Cardiac EQA programme is designed to monitor the performance of up to 9clinically significant cardiac markers including: CK-MB mass, D-dimer, Digoxin, homocysteine, hsCRP, myoglobin, NT proBNP, troponin I, and troponin T. RIQAS is ISO/IEC 17043 accredited and allows the registration of up to five instruments at no extra cost. All samples are 100% human serum and provided in a liquid ready-to-use format for enhanced convenience. Submit your results bi-weekly and view reports online via RIQAS.Net. For more information on RIQAS, the world’s largest international EQA scheme, please click here or email firstname.lastname@example.org
For further information, please contact the Randox PR team via email: email@example.com or phone 028 9442 2413